Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy

Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy - Thermo Fisher Scientific (NYSE:TMO), Ar - Benzinga Benzinga España Italia 대한민국 日本 Français My Account Benzinga Edge Benzinga Research Benzinga Pro Login Get Benzinga Pro Data & APIs Events Premarket Advertise Contribute España Italia 대한민국 日本 Français Login Register Benzinga Premium Services Financial News Financial News Large Cap Stocks Small-Cap Stocks Insider Trades Earnings Technology AI News Personal Finance ETF News Crypto News Dividend News Latest Rumors Latest Offerings News Investment Ideas Investment Ideas Stock of the Day Stock Whisper Index Analyst Ratings Analyst Color Financial Advisors Government Trades Trading Ideas Stock Screener Markets Markets Premarket Movers After Hours Options ETFs Commodities Prediction Markets Private Markets Bonds Futures Forex Top Stocks Top Stocks Apple (AAPL) Tesla (TSLA) Amazon (AMZN) Nvidia (NVDA) Alphabet (GOOGL) Meta Platforms (META) Microsoft (MSFT) StreetTracks Gold Shares (GLD) IBIT Bitcoin Trust (IBIT) Top Value Stocks Top Momentum Stocks Top Growth Stocks Top Quality Stocks Learn Learn Investing Guides Personal Finance Mortgages Best Credit Cards Best Dividend Stocks Best Swing Trade Stocks Investment Ideas Investment Ideas Stock of the Day Stock Whisper Index Analyst Ratings Analyst Color Financial Advisors Government Trades Trading Ideas Stock Screener Markets Markets Premarket Movers After Hours Options ETFs Commodities Prediction Markets Private Markets Bonds Futures Forex Top Stocks Top Stocks Apple (AAPL) Tesla (TSLA) Amazon (AMZN) Nvidia (NVDA) Alphabet (GOOGL) Meta Platforms (META) Microsoft (MSFT) StreetTracks Gold Shares (GLD) IBIT Bitcoin Trust (IBIT) Top Value Stocks Top Momentum Stocks Top Growth Stocks Top Quality Stocks Learn Learn Investing Guides Personal Finance Mortgages Best Credit Cards Best Dividend Stocks Best Swing Trade Stocks Research My Stocks Tools Free Benzinga Pro Trial Calendars Analyst Ratings Calendar Conference Call Calendar Dividend Calendar Earnings Calendar Economic Calendar Events Calendar FDA Calendar Guidance Calendar IPO Calendar M&A Calendar Unusual Options Activity Calendar SPAC Calendar Stock Split Calendar Trade Ideas Stock Reports Insider Trades Trade Idea Feed Analyst Ratings Unusual Options Activity Heatmaps Free Newsletter Government Trades Perfect Stock Portfolio Easy Income Portfolio Short Interest Most Shorted Largest Increase Largest Decrease Calculators Options Profit Calculator Margin Calculator Forex Profit Calculator 100x Options Profit Calculator Covered Call Calculator Cash-Secured Put Calculator Long Call Calculator Long Put Calculator Screeners Stock Screener Top Momentum Stocks Top Quality Stocks Top Value Stocks Top Growth Stocks Compare Best Stocks Best Momentum Stocks Best Quality Stocks Best Value Stocks Best Growth Stocks Recent Markets July 2, 2026 11:32 AM 2 min read Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy Thermo Fisher To Support Phase 3 Development The collaboration brings together Thermo Fisher’s Accelerator Drug Development solutions, which combine manufacturing and clinical research capabilities, to support ARCT-032 through late-stage development and potential commercialization . Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services while Arcturus continues advancing the ARCT-032 program. The partnership is designed to streamline development by integrating manufacturing, clinical research, and commercial readiness services as the investigational therapy moves toward its next stage. Commercial Manufacturing Planned If Therapy Wins Approval Arcturus said it expects to conduct its Phase 3 clinical program through Thermo Fisher’s PPD clinical research business if its ongoing Phase 2 study produces positive results . The agreement also outlines a potential commercial relationship beyond clinical development. Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement. ARCT-032 is an inhaled mRNA therapeutic candidate for cystic fibrosis, a rare genetic disease . Arcturus initiated enrollment of a new cohort in March 2026. The open-label Phase 2 clinical study is currently enrolling up to 20 participants . The study will monitor 10 mg dosing over 12 weeks for safety and evidence of early clinical benefits, including assessment of lung functional improvements, two validated quality‑of‑life outcome measures, and evaluation of any changes in high-resolution computed tomography imaging. ARCT Stock Price Activity : Arcturus Therapeutics shares were up 12.19% at $7.73 at the time of publication on Thursday, according to Benzinga Pro data . Photo: Shutterstock Market News and Data brought to you by Benzinga APIs © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. To add Benzinga News as your preferred source on Google, click he